Skip to main content

Advertisement

Table 1 Used drugs, Cmax, AUC levels

From: Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells

Drug groups Drug name Brand name, company In vitroused concentrations (μg/ml) Cmax Value (μg/ml) In vivodose (Cmax) AUC (μg × h/ml) In vivodose (AUC) Reference
anthracyclines epirubicin Epirubicin Meda, Meda 0.026–1.66 9 120 mg/m2 2.412 90 mg/m2 (Fogli et al. 2002) [23]
  daunorubicin Cerubidin®, Aventis Pharma 0.065–4.166 0.49 0.95 mg/kg in 45 min 1.2786 1.5 mg/kg (Andersson et al. 1979) [6]
  doxorubicin Doxorubicin Teva, Teva 0.026–1.66 0.93 50 mg/m2 0.82464 50 mg/m2 (Toffoli et al. 2004) [24]
epipodophyllotoxin etoposide Sigma 0.325–20.833 2.5 53 mg/m2/day 5.06 100 mg/m2/day (Minami et al. 1995) [25] (Gruber et al.1995) [26]
camptothecins topotecan Hycamtin®, GlaxoSmithKline 0.052–3.33 0.0084 2.3 mg/m2/day 0.0196 1.2 mg/m2/day (Gerrits et al. 1999) [27]
taxanes paclitaxel Taxol, Orifarm 0.078–5 3.38 175 mg/m2 by 3 h 13.49 175 mg/m2 (Fogli et al. 2002) [23]
  docetaxel Taxotere®, Aventis Pharma 0.52–33.33 2 60 mg/m2 3.326 85 mg/m2 (Rischin et al. 2002) [28]
vinca alkaloids vincristine Vincristine Mayne, Mayne Pharma 0.0065–0.416 0.37 1.4 mg/m2 0.182 1.32 mg/m2 (Terashi et al. 2000) [29] (Desai et al. 1982) [30]
  vinblastine Velbe®, STADApharm 0.013–0.833 0.005 1.5 mg/m2 by 24 h 0.218 1.7 mg/m2 (Stewart et al. 1983) [31] (Bates et al.) [32]
  vinorelbine Navelbine®, Pierre Fabre 0.13–8.33 0.83 200 mg/week 0.899 80 mg/m2/week (Zhou et al. 1991) [33] (Freyer et al. 2003) [34]
platinum analogs carboplatin Carboplatin Mayne, Mayne Pharma 0.13–8.33 0.046 360 mg/m2 348000 360 mg/m2 (Ghazal-Aswad et al. 1996) [35]
  oxaliplatin Eloxatin, Sanofi-Synthelabo 0.065–4.166 3.2 130 mg/m2 71.5 130 mg/m2 (Gamelin et al. 1997) [36] (Graham et al. 2000) [37]
antifolate methotrexate Methotrexate Pharmacia, Pfizer 0.325–20.833 363 8–12 g/m2 13200000 12 g/m2 (Bacci et al. 2006) [38] (Crews et al. 2004) [39]
purin antagonists 6-mercaptopurine Sigma 1.085–69.44 2 2.5 mg/kg oral dose 0.2587 85 mg/m2 (Chan et al. 1989) [26]
  cladribine Leustatin, Janssen-Cilag 0.013–0.833 0.0356 5 mg/m2 0.1541 5 mg/m2 (Albertioni et al. 1998) [40]
pyrimidine antagonists fluorouracil Fluorouracil Mayne, Mayne Pharma 0.65–41.66 55.4 400 mg/m2 11.59 400 mg/m2 (Casale et al. 2004) [41]
  cytarabine Cytarabine Pfizer, Pfizer 1.302–83.33 10.8 3 g/m2 523.4 1 g/m2 (DeAngelis et al. 1992) [42] (Gruber et al. 1995) [26]
  gemcitabine Gemzar, Orifarm 0.781–50 22.3 1000 mg/m2 9.3 1000 mg/m2 (Fogli et al. 2002) [23]
antitumor antibiotics bleomycin Bleomycin Baxter, Baxter 0.39–25* 0.19* 30 IU/day 0.089 8 IU/kg/day (Broughton et al. 1977) [43] (Peng et al.1980) [44]
  dactinomycin Cosmegen®, MSD 0.006–0.416 0.1 1.5 mg/m2 300 1.5 mg/m2 (Veal et al. 2005) [45]
protease inhibitors bortezomib Velcade®, Janssen-Cilag 0.013–0.833 0.08 1.45 mg/m2 0.0438 1.45 mg/m2 (Papandreou et al. 2004) [46]
  MG132 Sigma 0.13–8.33 #     
alkylating agents cyclophosphamide Sendoxan, Baxter 0.52–33.33 37.2 50 mg/kg 367 50 mg/kg (Xie et al. 2006) [47]
  ifosphamide Holoxan®, Baxter 0.52–33.33 56.63 16 g/m2 in 96 h 1827.7 3 g/m2/day (Wright et al. 1995) [48] (Boddy et al. 1996) [45]
  chlorambucil Sigma 1.302–83.33 0.49 0.2 mg/m2 0.883 0.2 mg/m2 (GlaxoSmithKline Research Triangle Park) [49]
  streptozotocin Sigma 0.65–41.66 ¤     
miscellaneous asparaginase Asparaginase Medac, Medac 0.065–4.166* 4.48* 10000 IU/m2 0.943 30000 IU/m2 (Ho et al. 1981) [50] (Ylikangas et al. 2002) [51]
  hydroxyurea Sigma 0.65–41.66 21 18 mg/kg 82.49 15 mg/kg (Gwilt et al. 2003) [52] (Yan et al. 2005) [46]
  prednisolone Di-Adreson F Aquosum, Organon 1.56–100 0.325 1 mg/kg/day 1.33 1 mg/kg/day (Rostin et al. 1990) [53]
  1. Cmax: maximum plasma level after administration of the clinical dose of the drug
  2. *In case of bleomycin and asparaginase concentrations are in IU/ml
  3. AUC: area under curve
  4. #: not used in the clinical practice
  5. ¤: no data is available